The World Health Organisation has given its nod to the first malaria vaccine RTS,S (trade name Mosquirix), which has been developed by GlaxoSmithKline.
The World Health Organisation has given its nod to the first malaria vaccine RTS,S (trade name Mosquirix), which has been developed by GlaxoSmithKline. Dr Satyajit Rath, an immunologist and adjunct faculty at IISER, Pune, discusses with Newsclick editor-in-chief Prabir Purkayastha the implication of Mosquirix and its role in the fight against malaria in Global South. He further explains how private companies aim to profit from the vaccine with malaria being a “disease of the poor”.